Molecular Partners AG (MOLN)
3.87
+0.16
(+4.31%)
USD |
NASDAQ |
May 16, 16:00
Molecular Partners Free Cash Flow: -66.61M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
December 31, 2023 | -66.61M |
September 30, 2023 | -63.16M |
June 30, 2023 | -66.63M |
March 31, 2023 | -71.87M |
December 31, 2022 | 122.83M |
Date | Value |
---|---|
September 30, 2022 | 114.79M |
June 30, 2022 | 113.19M |
March 31, 2022 | 108.94M |
December 31, 2021 | -100.94M |
Free Cash Flow Range, Past 5 Years
-100.94M
Minimum
Dec 2021
122.83M
Maximum
Dec 2022
10.06M
Average
-63.16M
Median
Sep 2023
Free Cash Flow Benchmarks
AC Immune SA | -48.92M |
CRISPR Therapeutics AG | -169.05M |
Addex Therapeutics Ltd | -8.908M |
NLS Pharmaceutics Ltd | -9.684M |
MoonLake Immunotherapeutics | -48.91M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | -17.00M |
Cash from Investing (Quarterly) | 21.20M |
Cash from Financing (Quarterly) | -0.3157M |
Free Cash Flow Per Share (Quarterly) | -0.5277 |
Free Cash Flow to Equity (Quarterly) | -17.34M |
Free Cash Flow to Firm (Quarterly) | -17.34M |
Free Cash Flow Yield | -53.78% |